A total of 418 patients receiving hematopoietic SCT and surviving beyond day 100 were examined for the occurrence of large granular lymphocytes (LGLs).
INTRODUCTION
Large granular lymphocytes (LGLs) are morphologically distinct but represent an immune-phenotypically heterogeneous lymphocyte population comprising activated CD3 þ T cells or CD3 À natural killer (NK) cells that mediate non-MHC-restricted cytotoxicity. 1, 2 LGL can be activated as a result of constant antigenic stimulation in various clinical situations such as allogeneic hematopoietic SCT, 3 solid organ transplantation and chronic infections particularly related to CMV 4, 5 or VZV. 6 A number of reports have described a rapid reccurence of LGLs early after autologous and allogeneic hematopoietic SCTs in small series of patients.
5,7-10 Dolstra et al. 10 evaluated a cohort of 46 patients over a period of 1 year and demonstrated in 45% of patients an increase of cells with flow cytometric parameters consistent with LGLs above normal levels. These patients had a lower incidence of relapse. A longitudinal study over 7 years by Mohty et al. 5 identified six cases in 201 consecutive recipients. The expansion of LGLs was observed transiently or chronically (X6 months) and was usually associated with CMV reactivation, other infectious complications and seen in patients with GVHD. As in the study by Dolstra et al. 10 these patients tended to demonstrate a lower relapse rate, thus implying that LGLs may have a role in mediating a GVL effect.
The current study represents a detailed review of 418 patients transplanted in a single centre with the objective to define the cumulative incidence of LGL lymphocytosis, to identify associations with tranplant related clinical parameters and to assess the impact on transplant related outcomes.
PATIENTS AND METHODS

Transplant procedures
A retrospective study was conducted on 418 consecutive recipients of stem cell allografts that had survived more than 100 days after transplant. The transplants were performed between January 2000 and October 2007 at the Princess Margaret Hospital, Toronto, Canada, using related (n ¼ 333), including syngeneic donors (n ¼ 4) and unrelated donors (n ¼ 85). Institutional research board approval of the retrospective data collection and analysis was obtained. The transplant procedures and post-transplant management strategies adhered to previously described institutional policies. [11] [12] [13] [14] [15] [16] Post-transplant G-CSF support was not routinely administered.
GVHD prophylaxis and treatment
The majority of patients (n ¼ 413), received GVHD prophylaxis with CSA based regimens. CSA was used either alone (n ¼ 27) or in combination with MTX (n ¼ 275), mycophenolate mofetil (n ¼ 111). GVHD treatment was prescribed according to the center's policy as previously published. [11] [12] [13] [14] [15] [16] Evaluation of large granular lymphocytosis Following the transplant, patients were regularly monitored with peripheral blood counts and automated differentials on a regular basis (that is, every 2-4 weeks). Blood films of samples with X3.0 Â 10 9 /L lymphocytes were routinely assessed morphologically for the presence of LGLs using standard criteria 17 as cells with distinctive morphological features, including large-sized cytoplasm with round to indented nuclei, coarse chromatin and azurophilic cytoplasmic granules. A subset of samples with morphologically identified LGLs was subjected to immune phenotyping by flow cytometry for the presence of CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD56 and CD57 positive cells. Peripheral blood samples of some patients were examined for T-cell receptor gene rearrangement by PCR to determine clonality. In addition, serologic studies were conducted for hepatitis B virus, hepatitis C virus, VZV and human T-lymphotropic virus type I.
Definitions
The day of the stem cell infusion was defined as day 0. Engraftment was defined as an ANC above 0.5 Â 10 9 /L for two consecutive days and peripheral platelet counts exceeding 20 Â 10 9 /L for at least three consecutive days without transfusion.
Disease risk was defined as described previously. 18 Acute and chronic GVHD were diagnosed and graded using established criteria. 19, 20 The incidence of relapse was defined according to the time from transplantation until disease progression. NRM was defined as death not related to disease recurrence or progression. OS was defined as the time from transplantation until death from any cause.
LGL lymphocytosis was defined as the presence of at least two of the following criteria: (1) sustained lymphocytosis above 3.0 Â 10 9 /L observed in at least three consecutive determinations over a time frame of 2-3 months, (2) predominance (that is, 430%) of LGLs in the peripheral blood, (3) confirmation of monoclonality by T-cell receptor analysis using PCR. The first date with lymphocytes equal to or above 3 Â 10 9 /L was considered as the day of onset. The duration of LGL lymphocytosis was calculated from the day of onset to the last day with lymphocyte counts equal to or above 3 Â 10 9 /L.
Statistical analysis
The cumulative incidence of LGL lymphocytosis was estimated considering death as a competing risk. The probabilities of OS were estimated by Kaplan-Meier methods, while the cumulative incidence of GVHD was estimated considering death as a competing risk. The cumulative incidence of NRM was estimated using relapse as a competing risk, and relapse incidence using death not related to relapse (that is, NRM) as a competing risk. Transplantation outcomes were compared by the log-rank test or Gray's test as appropriate. Patient related characteristics, transplantation procedures and outcomes were compared with respect to the LGL lymphocytosis using w 2 , Fisher's exact or Mann-Whitney's U-tests as appropriate. Data were evaluated using two different statistical approaches. The initial assessment used nontime dependent Cox's proportional hazard model to examine the impact of LGL on transplant outcomes. The prognostic impact of clinical factors on OS, NRM and relapse incidence was examined by uni-and multivariate analyses. Parameters tested by univariate analysis included occurrence of LGL lymphocytosis, conditioning regimen (myeloablative vs reduced intensity, disease risk (low or intermediate vs high risk), age of recipients (p50 years vs 450 years), acute GVHD (grade 0-2 vs grade 3-4), and chronic GVHD (absent vs present). Variables with P-values p0.1 in the univariate analyses, were included into the second analysis. In a second approach, the analysis was expanded to utilize a time-dependent Cox's proportional hazard model to adjust for time-dependent effects related to LGL lymphocytosis on OS, NRM and relapse. Three time-dependent variables were included: LGL lymphocytosis, acute GVHD and chronic GVHD. Multivariate analyses were performed including three timedependent variables as well as non-time dependent variables for transplant outcomes.
Next, in order to identify clinical factors for the development of LGL lymphocytosis, uni-and multivariate analyses was performed based on a Cox proportional hazard model. The univariate analyses included the following parameters: conditioning regimen (myeloablative vs reduced intensity), HLA matching (matched vs mismatched), donor type (sibling vs alternative), disease risk (low or intermediate vs high risk), serostatus of CMV Ab in donor/recipient, episode of CMV antigenemia, acute GVHD (grade 0-2 vs grade 3-4), and chronic GVHD (absent vs present). Variables with P-values p0.1 were included into the multivariate analysis. In addition, a time-dependent Cox's proportional hazard model was adopted to take into account the time-dependent effect of CMV antigenemia and chronic GVHD on the development of LGL lymphocytosis.
P-values of less than 0.05 were considered statistically significant. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated with a predetermined reference risk of 1.0. SPSS software package (SPSS 13.0 Inc. Chicago, IL, USA) and SAS version 9.2 (SAS Institute, Cary NC, USA) were used for the statistical analyses.
RESULTS
Overall transplant outcomes
With a median follow-up of 36 months for survivors (range 4-93 months), the 3-year OS, NRM and relapse incidence rates were 52.7 ± 2.4, 21.7 ± 2.3 and 26.0 ± 2.5%, respectively. The cumulative incidence of acute GVHD grades 2-4 and grades 3/4 was 76.5±2.2 and 44.8±3.3% at day 100. The cumulative incidence of overall and extensive chronic GVHD at 2 years was 88.9 ± 1.9 and 63.3 ± 2.8% with a median onset of 131 and 196 days, respectively. CMV antigenemia was observed in 174 patients (41.6%) with a median onset of 43 days (range 13-251 days) post-transplant. The median times to neutrophil and platelet engraftment were 19 and 15 days, respectively.
Incidence of LGL lymphocytosis following allogeneic hematopoietic SCT Seventy seven of the 418 recipients (18.4%), included into the study met the morphological criteria for LGL lymphocytosis. Clinical details of these patients and their transplant outcomes are summarized in Tables 1 and 2 . Increased LGL values after allografting were observed as early as 26 days after transplantation. However, only patients suviving more than 100 days were entered into the study. The median onset of LGL lymphocytosis occurred at 312 days (range 26-1840 days) after transplant with a median duration of 463 days (95% CI 90-2082 days). The incidence of LGL lymphocytosis at 1, 2 and 3-years was 12.3 ± 1.8, 20.8 ± 2.4 and 23.6 ± 2.7% ( Figure 1a ). The incidence was independent of the administration of a myeloablative or reduced intensity preparative regimen (22.7±3.0% and 24.7±5.3%, respectively) ( Figure 1b ). The occurrence of increased LGL values was preceded by the development of limited (median onset 140 days, range 80-741 days) or extensive chronic GVHD (median onset 267 days, range 96-1275 days) in 54 patients. In 20 patients, LGL lymphocytosis was diagnosed before the development of chronic GVHD.
None of the 77 patients experiencing LGL lymphocytosis had shown unexplained fever, night sweats, weight loss or lymphadenopathy suggestive of lymphoproliferative neoplasms. Pancytopenia and proteinuria was noted in four and two patients, respectively. With a maximum follow-up of 93 months none of the patients demonstrating increased LGL values has progressed to LGL leukemia or any other lymphoproliferative disorder.
Samples from 41 patients were phenotyped by flow cytometry. These studies confirmed a T cell phenotype of LGLs in the majority of patients (n ¼ 32). Two patients presented with LGLs consistent with NK cells and seven showed properties of a mixed NK/T-cell lineage. In addition, T-cell receptor studies were performed on peripheral blood samples of 10 patients. A monoclonal LGL population of T-cell origin was identified in nine of these patients. One patient for whom a monoclonal T cell population could not be confirmed presented with LGLs of NK phenotype.
The clinical outcomes of patients with LGL lymphocytosis confirmed by flow cytometry were compared with those diagnosed only by morphological criteria. No statistically significant differences were observed for risk of acute GVHD, chronic GVHD, relapse and OS. The rate of CMV antigenemia was higher in the group of patients confirmed by flow cytometry (data not shown).
Chimerism studies were performed on peripheral blood samples of 24 patients with LGL lymphocytosis. All but one demonstrated a presence of 97-98% donor cells. The exception was a patient with 57.7% of donor cells. Post-transplant serological studies for hepatitis B virus, hepatitis C virus, HIV and human T-lymphotropic virus type 1 performed in 255 patients revealed three positive cases for hepatitis B virus and one for hepatitis C virus. A correlation with the development of LGL lymphocytosis could not be established for positive patients.
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Prognostic implication of LGL lymphocytosis on transplant outcomes
In order to analyze the prognostic impact of LGL lymphocytosis on transplant outcomes, we compared OS, and incidence of NRM and relapse for patients with and without LGL lymphocytosis. The analysis was performed using two different statistical methods as outlined in the Patients and Method section.
The presence of increased LGL values was associated with improved OS (86.2±4.6 vs 53.8±3.0% at 3 years, Po0.001), lower NRM (3.2 ± 2.2 vs 27.3 ± 2.9% at 3 years, Po0.001) and lower relapse rate (9.6 ± 3.8 vs 29.4 ± 2.9% at 3 years, Po0.001) (Figure 2) .
A multivariate analysis using a time dependent Cox's proportional hazard model was performed to evaluate the contribution of LGL lymphocytosis to OS, NRM and relapse incidence in the context of other potentially relevant clinical parameters (Table 3) .
LGL lymphocytosis was confirmed to be an independent favorable prognostic factor for OS (P ¼ 0.0226, HR 0.427 95% CI (0.205-0.887)) and for NRM (P ¼ 0.0259, HR 0.798 95% CI (0.048-0.823)). It also showed a trend of preventive factor for relapse (P ¼ 0.0768, HR 0.394 95% CI (0.141-1.105) in the timedependent Cox's proportional hazard models. Chronic GVHD, disease risk and age of recipients retained their prognostic value for OS besides LGL lymphocytosis. In summary, the use of timedependent Cox's proportional hazard models confirmed the presence of LGL lymphocytosis as an independent favorable prognostic indicator for OS and NRM (Table 3) . In addition, patients with LGL lymphocytosis showed a trend to reduced relapse risk (Table 3) .
Predictive factors for LGL lymphocytosis following transplantation In order to identify predictive factors for the development of LGL lymphocytosis, we compared the groups with and without LGL lymphocytosis according to the following variables: conditioning regimen (myeloablative vs reduced intensity), stem cell source (BM vs PBSC), HLA matching (matched vs mismatched), donor type (sibling vs alternative), disease risk (low or intermediate vs LGL lymphocytosis after allo-SCT D (Dong Hwan) Kim et al high risk), serostatus of CMV Ab in donors and in recipients, episode of CMV antigenemia, episode of VZV infection, acute GVHD (grade 0-2 vs grade 3-4) and chronic GVHD (absent vs present). Three risk factors were identified: CMV serostatus of the recipient (Figure 3a) , CMV antigenemia (Figure 3b) , and occurrence of chronic GVHD (Figure 3c) . A higher incidence of LGL lymphocytosis was noted: (1) in CMV seropositive (CMV-R þ ) compared with CMV seronegative recipients (CMV-R À ) regardless of CMV serostatus of the donor (Po0.001; Figure 3d ); (2) in patients with CMV reactivation (Po0.001); and (3) in patients developing chronic GVHD (P ¼ 0.007). No other factors were found to be associated with the development of LGL lymphocytosis following hematopoietic SCT.
As shown in Figure 3d , a subset analysis based on the CMV serostatus of recipient/donor showed the highest incidence of LGL lymphocytosis with 38.8±5.6% at 3-years for the CMV-R þ /D showed an incidence of 12.6 ± 6.2% and 8.3 ± 3.2%, respectively. This result confirms the importance of the recipient CMV serostatus regardless of donor CMV serostatus. When both, the CMV status of the recipient and the occurrence of chronic GVHD were considered the group with CMV-R þ and chronic GVHD þ presented with the highest incidence of LGL lymphocytosis of 43.2±6.0% at 3-years, while those with CMV-R þ and chronic GVHD À status showed an incidence of 35.0 ± 7.7% (Figure 3e) . A much lower incidence was seen in CMV-R À /chronic GVHD þ and CMV-R À /chronic GVHD À patients. Their respective incidence of LGL lymphocytosis at 3-years post-transplant was 6.7 ± 6.4 and 3.2 ± 3.2%.
Risk factors for the development of LGL lymphocytosis identified by univariate analysis were entered into a timedependent Cox proportional hazard model. A time-dependent Cox's proportional hazard model was constructed to evaluate the occurrence of CMV antigenemia and chronic GVHD as timedependent variables and their impact on the development of LGL lymphocytosis. Both were confirmed as significant risk factors with a P-value for chronic GVHD of 0. Table 4 ).
DISCUSSION
A number of reports on small series of recipients of autologous and allogeneic hematopoietic SCTs have described increased numbers of LGLs in some patients following the transplant. These studies were usually performed to characterize the biological properties of these cells. The predominant phenotype demonstrated coexpression of CD8 þ /CD57 þ by flow cytometry, and demonstrated cytotoxic effects against targets such as K562 cells. Their clinical significance was addressed in studies by Dolstra et al. 10 and Mothy et al. 5 in cohorts of 46 and 201 transplant recipients, respectively. Both studies suggested a benefit for patients with LGL lymphocytosis related to a decreased relapse rate. The incidence of LGL lymphocytosis following transplant is not well established. In part this deficiency is related to studies LGL lymphocytosis after allo-SCT D (Dong Hwan) Kim et al with small patient numbers as well as varying definitions for LGLs. The study by Mothy et al. 5 encompassing so far the largest number of patients resulted in the identification of six individuals with elevated LGL levels in a cohort of 201 consecutively transplanted individuals.
Our current study on 418 consecutive allogeneic transplant recipients was designed with three objectives: to determine the cumulative incidence of LGL lymphocytosis in a larger patient population, to identify potential associations with transplant related clinical parameters and to assess the impact on transplant related outcomes. A cumulative incidence of 20% at 2 years posttransplant was observed. This was based on the definition of LGLs as cells with distinctive morphological features, including largesized cytoplasm with round to indented nuclei, coarse chromatin and azurophilic cytoplasmic granules. These cells are immune phenotypically heterogeneous and comprise lymphocyte populations of activated CD3 þ T cells or CD3 À NK cells. The majority of patients (78%) in this report belonged to the T cell lineage, 17% presented with LGLs consistent with the NK/T cell lineage, and 5% with LGLs of NK cell type. The time of their appearance post-transplant varied from 26-1840 days with a median of 312 days. Considerable variation was observed for the duration of LGL elevations. It is of note, that in our study neither the time of emergence, nor the duration of increased LGLs influenced outcome during the observation period. However, the incidence of LGL lymphocytosis in the present study should be interpreted with caution as only 41 out of 77 patients with morphologically determined LGL lymphocytosis were confirmed by flow cytometry.
There was a strong association of LGL lymphocytosis with chronic GVHD, CMV status of the recipient and CMV antigenemia. The highest incidence was observed for CMV positive recipients that developed chronic GVHD in the majority of patients. It is of note that in our study chronic GVHD appears to antecede the occurrence of elevated LGL levels. This is consistent with the suggestion by Mohty et al. 5 that LGL lymphocytosis may emerge generally in the context of chronic Ag stimulation associated with GVHD in allograft recipients as well as recurrent CMV infections, or other chronic Ag stimulations after autologous or allogeneic hematopoietic SCT. There is evidence that primary CMV infections may activate monoclonal LGL expansion, [21] [22] [23] with persistence even after successful resolution of the CMV infection. 23 After allogeneic hematopoietic SCT, CMV reactivation may trigger activation of LGL expansion so that these LGL cells persist even after controlling for CMV reactivation.
Patients presenting with LGL lymphocytosis demonstrated statistically significantly better transplant outcomes in the form of prolonged OS, lower NRM and a trend to lower relapse risk. This conclusion was derived from multivariate analysis using a timedependent Cox's proportional hazard model. The mechanisms for improved outcomes after transplantation are not clearly established. One may speculate that longer living patients may simply have a greater chance to develop LGL lypmphocytosis without
LGLs actually contributing to improved outcomes. However, our result from time-dependent Cox's proportional hazard model excludes the effect of longevity on the occurrence of LGL lymphocytosis. Alternatively, one may have to consider the contribution made by chronic GVHD as the primary mechanism, as in this study LGL lymphocytosis commonly occurred after the onset of chronic GVHD. The benefit may result from a direct immune mediated effect of LGLs 24, 25 inducing tumor lysis. This explanation is supported by investigations reported by Mohty et al. 3, 5 demonstrating their cytolytic activity in vitro using a CR 51 release assay. This observation is consistent with the view that
LGLs represent a subset of effector lymphocytes responsible for the GVL effect after hematopoietic SCT. Emerging
LGLs after allogeneic transplantation are likely graft derived as shown by chimerism studies on a small number of our patients. Their interaction with host tissues still remains unclear. In a rat model of GVHD LGLs were found to transiently infiltrate the liver if affected by GVHD. 26, 27 This may represent a site of Ag exposure. Subsequently they disappear from the liver and appear to migrate to the spleen. These observations support the LGL lymphocytosis after allo-SCT D (Dong Hwan) Kim et al LGL lymphocytosis after allo-SCT D (Dong Hwan) Kim et al hypothesis that
LGLs recognize Ag early during GVHD and migrate to expand in lymphohemopoietic tissues. In addition, chronic stimulation by chronic antigenic exposure during chronic GVHD might contribute to further expansion of LGLs. However, additional study is strongly warranted to explore the mechanism of their activation and expansion in transplant recipients particularly to clarify the effect of GVHD on the occurrence of LGL lymphocytosis.
In conclusion, LGL lymphocytosis following allogeneic hematopoietic SCT is relatively common with an incidence of 20% at 2 years. LGL lymphocytosis is associated with favorable transplant outcomes including increased OS, lower NRM and a trend of lower relapse risk. Further prospective studies with larger numbers of patients will be required to determine the impact on long-term survival, control of the underlying disease. LGL lymphocytosis after allo-SCT D (Dong Hwan) Kim et al
